Rifaximine in therapy of gastrointestinal tract diseases: From the history of its creation to modern recommendations

1. Клинические рекомендации. Острые кишечные инфекции (ОКИ) у взрослых. Национальная ассоциация специалистов по инфекционным болезням им. академика В.И. Покровского (НАСИБ). Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 875_1. Доступ: https://cr.minzdrav.gov.ru/preview-cr/875_1 (дата обращения – 16.06.2025). (Clinical guidelines. Acute intestinal infections (AKI) in adults. National Association of Specialists in Infectious Diseases named after Academician V.I. Pokrovsky. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 875_1. URL: https://cr.minzdrav.gov.ru/preview-cr/875_1 (date of access – 16.06.2025) (In Russ.)).

2. Государственный доклад «О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2023 году». М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека (Роспотребнадзор). 2024; 364 с. Доступ: https://www.rospotrebnadzor.ru/upload/iblock/fbc/sd3prfszlc9c2r4xbmsb7o3us38nrvpk/Gosudarstvennyy-doklad-_O-sostoyanii-sanitarno_epidemiologicheskogo-blagopoluchiya-naseleniya-v-Rossiyskoy-Federatsii-v-2023-godu_..pdf (дата обращения – 16.06.2025). (State report “On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2023”. Moscow: Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor). 2024; 364 pp. URL: https://www.rospotrebnadzor.ru/upload/iblock/fbc/sd3prfszlc9c2r4xbmsb7o3us38nrvpk/Gosudarstvennyy-doklad-_O-sostoyanii-sanitarno_epidemiologicheskogo-blagopoluchiya-naseleniya-v-Rossiyskoy-Federatsii-v-2023-godu_..pdf (date of access – 16.06.2025) (In Russ.)).

3. Осадчук А.М., Лоранская И.Д., Осадчук М.А. Новые возможности и перспективы терапии функциональной патологии пищеварительного тракта. Consilium Medicum. 2023;25(12):844–848. (Osadchuk AM, Loranskaya ID, Osadchuk MA. Comorbid functional pathology in gastroenterology. Possibilities and prospects for drug treatment: A review. Consilium Medicum. 2023;25(12):844–848 (In Russ.)).

EDN: OHMLIC. https://doi.org/10.26442/20751753.2023.12.202529

4. Гурова М.М. Функциональные заболевания желудочно-кишечного тракта в педиатрической практике: от алгоритма диагностики к алгоритму лечения. Участковый педиатр. 2015(5):14–16. (Gurova MM. Functional gastrointestinal disorders in pediatric practice: From diagnostic algorithm to treatment algorithm. Uchastkoviy pediatr = District Pediatrician. 2015(5):14–16 (In Russ.)).EDN: SQRVWJ.

5. Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M. Functional disorders: Children and adolescents. Gastroenterology. 2016:S0016-5085(16)00181-5.

PMID: 27144632. https://doi.org/10.1053/j.gastro.2016.02.015. Online ahead of print.

6. Khan Z, Khan SK, Reyaz I, Anam H, Ijaz O, Attique I et al. Effectiveness of rifaximin on the outcomes of irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. Cureus. 2023;15(9):e44807.

PMID: 37809182. PMCID: PMC10558962. https://doi.org/10.7759/cureus.44807

7. World Health Organization. Antimicrobial resistance: Global report on surveillance. 2014. URL: https://www.who.int/publications/i/item/9789241564748 (date of access – 16.06.2025).

8. Koo HL, DuPont HL. Rifaximin: A unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol. 2010;26(1):17–25.

PMID: 19881343. PMCID: PMC4737517. https://doi.org/10.1097/mog.0b013e328333dc8d

9. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J et al.; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22–32.

PMID: 21208106. https://doi.org/10.1056/NEJMoa1004409

10. Mullen KD, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, Frederick RT et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2014;12(8):1390-7.e2.

PMID: 24365449. https://doi.org/10.1016/j.cgh.2013.12.021

11. Calanni F, Renzulli C, Barbanti M, Viscomi GC. Rifaximin: Beyond the traditional antibiotic activity. J Antibiot (Tokyo). 2014;67(9):667–70.

PMID: 25095806. https://doi.org/10.1038/ja.2014.106

12. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol. 2022;77(3):807–24.

PMID: 35724930. https://doi.org/10.1016/j.jhep.2022.06.001

13. Perrone V, Usala M, Veronesi C, Cappuccilli M, Esposti LD. Drug utilization of rifaximin-α in patients with hepatic encephalopathy: Evidence from real clinical practice in Italy. 2025;61(2):221.

PMID: 40005338. PMCID: PMC11857196. https://doi.org/10.3390/medicina61020221

14. Guo H, Lu S, Zhang J, Chen C, Du Y, Wang K, Duan L. Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study). Front Pharmacol. 2023;14:1121435.

PMID: 36873985. PMCID: PMC9974661. https://doi.org/10.3389/fphar.2023.1121435

15. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению препарата Альфа Нормикс® (200 мг). РУ: ЛП-№(006638)-(РГ-RU) от 22.08.2024. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=84effda6-652d-4dd8-a1d6-fbaba63cb218 (дата обращения – 16.06.2025). (State register of medicines of the Ministry of Healthcare of Russia. Instructions for medical use of the drug Alfa Normix® (200 mg). Registration certificate: ЛП-№(006638)-(РГ-RU) from 08/22/2024. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=84effda6-652d-4dd8-a1d6-fbaba63cb218 (date of access – 16.06.2025) (In Russ.)).

16. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению препарата Альфа Нормикс® (400 мг). РУ: ЛП-№(006080)-(РГ-RU) от 01.07.2024. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=471cf95b-de71-4b95-b4fa-d9653835bcd4 (дата обращения – 16.06.2025). (State register of medicines of the Ministry of Healthcare of Russia. Instructions for medical use of the drug Alfa Normix® (400 mg). Registration certificate: ЛП-№(006080)-(РГ-RU) from 07/01/2024. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=471cf95b-de71-4b95-b4fa-d9653835bcd4 (date of access – 16.06.2025) (In Russ.)).

17. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению препарата Альфа Нормикс® Форте. РУ: ЛП-№(004534)-(РГ-RU) от 07.02.2024. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=40ab757c-7ba4-4181-9df9-cfae89e55c7e (дата обращения – 16.06.2025). (State register of medicines of the Ministry of Healthcare of Russia. Instructions for medical use of the drug Alfa Normix® Forte. Registration certificate: ЛП-№(004534)-(РГ-RU) from 02/07/2024. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=40ab757c-7ba4-4181-9df9-cfae89e55c7e (date of access – 16.06.2025) (In Russ.)).

18. Gatta L, Scarpignato C. Systematic review with meta-analysis: Rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017;45(5):604–16.

PMID: 28078798. PMCID: PMC5299503. https://doi.org/10.1111/apt.13928

19. Li J, Ghosh TS, Arendt E, Shanahan F, O’Toole PW. Cross-cohort gut microbiome signatures of irritable bowel syndrome presentation and treatment. Adv Sci (Weinh). 2024;11(41):e2308313.

20. Fang G, Liu S, Liu B. Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: A network meta-analysis. BMC Gastroenterology. 2024;24(1):94.

PMID: 38439005. PMCID: PMC10910798. https://doi.org/10.1186/s12876-024-03184-0

21. Zacharias HD, Kamel F, Tan J, Kimer N, Gluud LL, Morgan MY. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2023;7(7):CD011585.

PMID: 37467180. PMCID: PMC10360160. https://doi.org/10.1002/14651858.CD011585.pub2

22. Ponziani FR, Zocco MA, D’Aversa F, Pompili M, Gasbarrini A. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. World J Gastroenterol. 2017;23(25):4491–99.

PMID: 28740337. PMCID: PMC5504364. https://doi.org/10.3748/wjg.v23.i25.4491

23. Шифрин О.С., Полуэктова Е.А., Королев А.В., Семенова Т.И., Шеин М.В., Лексикова Г.Н. с соавт. Российское неинтервенционное исследование эффективности и переносимости терапии рифаксимином-α у пациентов с неосложненной формой дивертикулярной болезни в условиях амбулаторной практики. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(1):14–25. (Shifrin OS, Poluektova EA, Korolev AV, Semenova TI, Shein MV, Leksikova GN et al. Russian non-interventional study of the efficacy and tolerability of rifaximin-α therapy in patients with uncomplicated diverticular disease under the conditions of outpatient practice. Rossiiskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(1):14–25 (In Russ.)).

EDN: YFYMPZ. https://doi.org/10.22416/1382-4376-2020-30-1-14-25

24. Prantera C, Lochs H, Grimaldi M, Danese S, Lia SM, Gionchetti P; Retic Study Group (Rifaximin-Eir Treatment in Crohn’s Disease). Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn’s disease. Gastroenterology. 2012;142(3):473–481.e4.

PMID: 22155172. https://doi.org/10.1053/j.gastro.2011.11.032

25. Lorenzetti R, Prantera C. Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results. Clinical Investigation. 2013;3(12):1187–93.

http://dx.doi.org/10.4155/cli.13.96

26. Клинические рекомендации. Язвенный колит. Общероссийская общественная организация «Ассоциация колопроктологов России», Российская гастроэнтерологическая ассоциация. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 193_2. Доступ: https://cr.minzdrav.gov.ru/preview-cr/193_2 (дата обращения – 16.06.2025). (Clinical guidelines. Ulcerative colitis. Association of Coloproctologists of Russia, Russian Gastroenterological Association. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 193_2. URL: https://cr.minzdrav.gov.ru/preview-cr/193_2 (date of access – 16.06.2025) (In Russ.)).

27. Rokkas T, Niv Y, Gisbert JP, Franceschi F, Gasbarrini A, Hold GL et al. The role of rifaximin in irritable bowel syndrome derived from a network meta-analysis of randomized control trials. Microb Health Dis. 2020;2:e333.

28. Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151:1113–21.

PMID: 27528177. https://doi.org/10.1053/j.gastro.2016.08.003

29. Oh CK, Chung HH, Kim YJ, Kim JB. Comparison of rifaximin monotherapy and rifaximin combined with probiotics in patients with irritable bowel syndrome: A randomized controlled trial. Nutrients. 2025;17(5):763.

PMID: 40077633. PMCID: PMC11901931. https://doi.org/10.3390/nu17050763

30. Huang J, Cheng C, Li Y, Liu Y, Liu Y. Efficacy and safety of rifaximin for the prophylaxis of hepatic encephalopathy: A meta-analysis. Medicine (Baltimore). 2025;104(5):e39905.

PMID: 39889173. PMCID: PMC11789876. https://doi.org/10.1097/MD.0000000000039905

31. Kimer N, Gluud LL, Morris RW, Morgan MY. Rifaximin for the prevention and treatment of hepatic encephalopathy: A systematic review with meta-analyses of randomised controlled trials. J Clin Exp Hepatol. 2017;7:S78–S79.

http://dx.doi.org/10.1016/j.jceh.2017.01.105

32. Клинические рекомендации. Цирроз и фиброз печени. Российская гастроэнтерологическая ассоциация, Российское общество по изучению печени. Рубрикатор клинических рекомендаций Минздрава России. 2021. ID: 715_1. Доступ: https://cr.minzdrav.gov.ru/view-cr/715_1 (дата обращения – 16.06.2025). (Clinical Guidelines. Liver Cirrhosis and Fibrosis. Russian Gastroenterological Association, Russian Society for the Study of the Liver. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2021. ID: 715_1. URL: https://cr.minzdrav.gov.ru/view-cr/715_1 (date of access – 16.06.2025) (In Russ.)).

33. Bianchi M, Festa V, Moretti A, Ciaco A, Mangone M, Tornatore V et al. Meta-analysis: Long-term therapy with rifaximin in the management of uncomplicated diverticular disease. Aliment Pharmacol Ther. 2011;33(8):902–10.

PMID: 21366632. https://doi.org/10.1111/j.1365-2036.2011.04606.x

34. Di Mario F, Miraglia C, Cambiè G, Violi A, Nouvenne A, Franceschi M et al. Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon. J Investig Med. 2019;67(4):767–70.

PMID: 30593541. https://doi.org/10.1136/jim-2018-000901

35. Muniyappa P, Gulati R, Hupertz V. Use of rifaximin in pediatric patients with inflammatory bowel disease: 1186. Am J Gastroenterol. 2007;102(Supplement):S551.

http://dx.doi.org/10.14309/00000434-200709002-01186

36. Macias P, Saldava N, Sandoval P et al. Efficacy and safety of rifaximin in the treatment of six-month to five-year-old children with acute diarrhoeal episodes. Rev Enf Inf Ped. 2002;16(61):23–28.

37. Scarpellini E, Giorgio V, Gabrielli M, Filoni S, Vitale G, Tortora A et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2013;17(10):1314–20. PMID: 23740443.

38. Клинические рекомендации. Синдром раздраженного кишечника. Союз педиатров России, общероссийская общественная организация «Ассоциация колопроктологов России», Российская гастроэнтерологическая ассоциация, межрегиональная общественная организация «Научное сообщество по содействию клиническому изучению микробиома человека», Российское общество детских гастроэнтерологов, гепатологов и нутрициологов. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 892_1. Доступ: https://cr.minzdrav.gov.ru/preview-cr/892_1 (дата обращения – 16.06.2025). (Clinical Guidelines. Irritable Bowel Syndrome. Union of Pediatricians of Russia, Association of Coloproctologists of Russia, Russian Gastroenterological Association, Scientific Society for the Promotion of Clinical Study of the Human Microbiome, Russian Society of Pediatric Gastroenterologists, Hepatologists and Nutritionists. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 892_1. URL: https://cr.minzdrav.gov.ru/preview-cr/892_1 (date of access – 16.06.2025) (In Russ.)).

39. Зырянов С.К., Байбулатова Е.А. Рифаксимин-альфа и другие кристаллические формы рифаксимина: есть ли отличия? Антибиотики и химиотерапия. 2020;65(7–8):52–62. (Zyryanov SK, Baybulatova EA. Rifaximin-alpha and other crystalline forms of rifaximin: Are there any differences? Antibiotiki i khimioterapiya = Antibiotics and Chemotherapy. 2020;65(7– 8):52–62 (In Russ.)).

EDN: YRWWTG. https://doi.org/10.37489/0235-2990-2020-65-7-8-52-62